Immunotherapy in tyrosine kinase inhibitor-naïve advanced epidermal growth factor receptor-mutant non-small cell lung cancer—driving down a precarious road in driver-mutated lung cancer

Benzer Materyaller

• Targeted Therapy For RET-Rearranged Non-Small Cell Lung Cancer: Clinical Development And Future Directions
  Yazar:: Ackermann, Christoph Jakob, ve diğerleri
  Baskı/Yayın Bilgisi: (2019)
• Erlotinib plus bevacizumab for EGFR-mutant advanced non-squamous non-small-cell lung cancer patients: ready for first-line?
  Yazar:: Adderley, Helen, ve diğerleri
  Baskı/Yayın Bilgisi: (2019)
• Overcoming resistance to first/second generation epidermal growth factor receptor tyrosine kinase inhibitors and ALK inhibitors in oncogene-addicted advanced non-small cell lung cancer
  Yazar:: Ourania Romanidou, ve diğerleri
  Baskı/Yayın Bilgisi: (2016-05-01)
• Overcoming resistance to first/second generation epidermal growth factor receptor tyrosine kinase inhibitors and ALK inhibitors in oncogene-addicted advanced non-small cell lung cancer
  Yazar:: Romanidou, Ourania, ve diğerleri
  Baskı/Yayın Bilgisi: (2016)
• Immunotherapy combined with epidermal growth factor receptor-tyrosine kinase inhibitors in non-small-cell lung cancer treatment
  Yazar:: Liang, Hongge, ve diğerleri
  Baskı/Yayın Bilgisi: (2018)